Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong healthcare momentum with concrete clinical and commercial support: shares rose 22.7% over 21 trading days, Q1 2026 revenue was $306.0M, ENCORE met its primary and key secondary endpoints, and pipeline activity includes TPIP Phase 3 initiation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Rally stalled ⢠Breakdown risk Support Level: $103-$106 Resistance Level: $109-$110 Over the last month, INSM has held support around $103-$106 but its rally has stalled under $109-$118, leaving it vulnerable to a break below $106-$107.
Sentiment & News
Key News Insights: ⢠TPIP efficacy ⢠Earnings catalyst ⢠Mixed ownership Insmed's positive 12-month TPIP extension data and upcoming Q2 earnings keep attention on a key growth catalyst, even as ownership changes and analyst coverage add mixed but active market interest.
AI Summary
INSM has moved from a pipeline story to a commercial execution story, so the key investment takeaway is that Brinsupri's launch pace and payer access must keep accelerating into the August 6 print to justify the current valuation, because any slowdown would quickly compress the multiple on a still-unprofitable base.
Description
Insmed is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases, and it markets ARIKAYCE for adult Mycobacterium avium complex lung disease as part of a combination antibacterial regimen. The companyâs pipeline includes Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor in development for bronchiectasis and other neutrophil-mediated conditions, and an inhaled treprostinil palmitil prodrug being studied for pulmonary arterial hypertension and other rare pulmonary disorders.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 8 | Jul 15 | INSM | Insmed Incorporated | Strong healthcare momentum with concrete clinical and commercial support: shares rose 22.7% over 21 trading days, Q1 2026 revenue was $306.0M, ENCORE met its primary and key secondary endpoints, and pipeline activity includes TPIP Phase 3 initiation. | Closed | -5.8% |
| Apr 1 | Apr 8 | INSM | Insmed Incorporated | Fresh positive Phase 3 ENCORE topline (3/23) and strong 2026 revenue guidance (BRINSUPRI âĽ$1B, ARIKAYCE $450â470M) have driven ~9.8% 21-day ROC and price ~13% above the 21-day SMA. With Phase 2b CEDAR topline due in Q2 2026, the stock is a high-risk but well-defined event-driven long for the coming days. | Closed | -2.8% |
| Nov 24 | Dec 1 | INSM | Insmed Incorporated | Insmed (INSM) is supported by FDA approvals, strong Q3 revenue growth (+22% ARIKAYCEÂŽ), bullish technical momentum (+24.5% over 21 days), and raised guidance reflecting commercial traction. Despite continuing losses and high valuation, ongoing pipeline catalysts and significant liquidity underpin a moderate short-term upside case. | Closed | +2.2% |